BlossomHill (BLSM) CFO Jason Keyes Buys Stock, Receives Award

What Happened

• Jason A. Keyes, Chief Financial Officer of BlossomHill Therapeutics (BLSM), made two reported transactions: an open-market purchase of 700 shares at $16.00 each (total $11,200) on 2026-08-10, and a grant of 56,746 derivative shares (recorded at $0) on 2026-08-06. The purchase is an outright buy (a straightforward acquisition); the larger grant is a derivative award that vests over time.

Key Details

• Transaction dates and prices:
  • 2026-08-10: Open market purchase — 700 shares @ $16.00 ($11,200).
  • 2026-08-06: Grant/award — 56,746 derivative shares @ $0.00 (no immediate cash outlay reported).
• Shares owned after the transactions: Not disclosed in the excerpt of the filing.
• Vesting footnote (F1): 1/4 of the shares subject to the award vest on August 6, 2027; the remainder vests in equal monthly installments over the following 36 months.
• Filing timeliness: Form 4 was filed on 2026-08-10. The grant dated 2026-08-06 was reported four days later, which may be later than the standard two-business-day Form 4 reporting requirement.

Context

• The 700-share open-market purchase is a direct purchase (a bullish signal in that it increases insider ownership), while the 56,746-share item is a time‑vested derivative award (typical executive compensation) and does not represent immediate free tradable shares. The vesting schedule means most of the awarded shares will not be transferable until future dates.